Speaker Bureau

Speaker Bureau

Learn more about XPHOZAH from leading experts

Meet Our Speakers
Mohammed S. Ahmed,
DO, FASN, CSH

Senior Consultant
Nephrology Associates of Northern Illinois

Oak Brook, IL

Rodolfo R. Batarsé,
MD, FASN

President, Desert Kidney Care Co-Director, Eisenhower Medical Center Graduate Medical Education in Nephrology

Rancho Mirage, CA

Vincent Carsillo II,
DO

Assistant Professor of Medicine, Albany Medical College

Albany, NY

Lisa Gutekunst,
MSEd, RD, CSR, CDN, FNKF

Ardelyx, Inc.

Waltham, MA

German Hernandez,
MD, FASN, FACP

El Paso Kidney Specialists Clinical Associate Professor of Medicine, Division of Nephrology & Hypertension, Texas Tech University Health Sciences Center

El Paso, TX

Pushkar Kanade,
MD, MPH

Medical Director of Nephrology Services, Great Plains Health Nephrology Medical Director of Outpatient Dialysis, Fresenius Medical Care

North Platte, NE

Wayne Kotzker,
MD

Physician Partner, Florida Kidney Physicians

Boca Raton, FL

Nelson P. Kopyt,
DO, FASN, FNKF, FACP, CPI

Clinical Professor of Medicine, Morsani College of Medicine Lehigh Valley Hospital Network

Allentown, PA

Andrew E. Lazar,
MD

Chief, Department of Nephrology, UH Ahuja Medical Center

Cleveland, OH

José A. Morfin,
MD, FASN

Health Sciences Clinic Professor, Director of Ambulatory Kidney Care Services, Outreach and Innovation, UC Davis School of Medicine

Sacramento, CA

Amy K. Mosman,
PA-C

Division of Nephrology, SLU Care Physician Group

St. Louis, MO

William R. Raffo,
MD

Clinical Nephrologist Medical Director, Sutter Health

Palo Alto, CA

Stuart Sprague,
DO, FASN, FACP

Professor of Medicine University of Chicago NorthShore-Endeavor Healthcare

Evanston, IL

Lauren E. Tarbox,
MD

South Texas Renal Care Group

San Antonio, TX

Get in touch.

Need more information on how to attend a speaker program?

RELATED LINKS

RD Engage

Video Hub

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Close

Connect with us for more information and continued updates about XPHOZAH.

Fill out the information below to register for updates.

*Required field.

Close

Close